eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
1/2021
vol. 37
 
Share:
Share:
abstract:
Review paper

Can the use of benzodiazepines increase the risk of dementia?

Jan Jaracz
1
,
Natalia A. Rakowska
1

  1. Department of Adult Psychiatry, Poznan University of Medical Sciences
Farmakoterapia w Psychiatrii i Neurologii 2021, 37 (1), 53–62
Online publish date: 2021/11/17
View full text Get citation
 
Objective
This study aims to provide up-to-date data on the possible relationship between the use of benzodiazepines and the subsequent occurrence of dementia.

Literature review
Benzodiazepines (BDA) have been used in medicine for over half a century. Initially, they were considered very safe, especially when compared to older generation drugs. Over time, more and more information about possible side effects became available and the problem of abuse and addiction was growing. One of the side effects of BDA is possible deterioration of cognitive functions, particularly relevant in elderly population. In recent years, numerous studies have been published, the results of which indicate the possible impact of using this group of drugs on the risk of developing dementia. The possibility of reverse causality, i.e. when BDA is included in the prodromal phase of dementia to alleviate such symptoms as anxiety or insomnia, is also discussed.

Conclusions
Although numerous studies confirm a higher incidence of dementia in BDA users, this relationship has not been clearly confirmed due to methodological problems and possible influence of many additional factors.

keywords:

dementia, benzodiazepines, prodromal symptoms


Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.